Scott Wolchko | President and CEO |
Ed Dulac | CFO |
Wayne Chu | SVP, Clinical development |
Michael Yee | Jefferies |
Mike Ulz | Morgan Stanley |
Alethia Young | Cantor |
Peter Lawson | Barclays |
Daina Graybosch | SVB |
Srikripa Devarakonda | Truist Securities |
Matt Biegler | Oppenheimer |
Mara Goldstein | Mizuho |
Nick Abbott | Wells Fargo |
Ted Tenthoff | Piper Sandler |
Rob Burns | H.C. Wainwright |
Welcome to the Fate Therapeutics Third Quarter 2021 Financial Results Conference Call. At this time all participants are in a listen-only mode. This call is being webcast live on the Investors section of Fate's website at fatetherapeutics.com.
As a reminder, today's call is being recorded. I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics.